Search results for "INTERFERON"

showing 10 items of 963 documents

Rationale for stimulator of interferon genes-targeted cancer immunotherapy

2017

International audience; The efficacy of checkpoint inhibitor therapy illustrates that cancer immunotherapy, which aims to foster the host immune response against cancer to achieve durable anticancer responses, can be successfully implemented in a routine clinical practice. However, a substantial proportion of patients does not benefit from this treatment, underscoring the need to identify alternative strategies to defeat cancer. Despite the demonstration in the 1990's that the detection of danger signals, including the nucleic acids DNA and RNA, by dendritic cells (DCs) in a cancer setting is essential for eliciting host defence, the molecular sensors responsible for recognising these dange…

0301 basic medicineCancer Research[SDV.IMM] Life Sciences [q-bio]/Immunologymedicine.medical_treatmentCancer immunotherapyBiologydanger signal03 medical and health sciencesImmune systemCancer immunotherapymedicine[ SDV.IMM ] Life Sciences [q-bio]/Immunologyinnate immunityInnate immune systemanticancer therapiesCancerImmunotherapyDNAadaptive immunityAcquired immune systemmedicine.diseaseeye diseases3. Good healthSting030104 developmental biologyOncologyStimulator of interferon genesImmunology[SDV.IMM]Life Sciences [q-bio]/ImmunologySTING
researchProduct

Chimeric Antigen Receptor-Engineered T-Cells - A New Way and Era for Lymphoma Treatment.

2019

Background: Patients with refractory or relapsed diffuse large B-cell lymphoma have a poor prognosis with the current standard of care. Objective: Chimeric Antigen Receptor T-cells (CAR T-cells) are functionally reprogrammed lymphocytes, which are able to recognize and kill tumor cells. The aim of this study is to make progress in this area. Method: A mini-review was achieved using the articles published in Web of Science and PubMed in the last year and the new patents were made in this field. Results: The responses to CAR T-cell products axicabtagene ciloleucel and tisagenlecleucel are promising; the objective response rate can reach up to 83%, and the complete response rate ranges betwee…

0301 basic medicineCancer Researchmedicine.drug_classmedicine.medical_treatmentT-LymphocytesMonoclonal antibodyImmunotherapy Adoptive03 medical and health sciences0302 clinical medicineInterferonDrug DiscoveryMedicineHumansPharmacology (medical)Clinical Trials as TopicReceptors Chimeric Antigenbusiness.industryGeneral MedicineImmunotherapymedicine.diseaseFusion proteinChimeric antigen receptorLymphomaCytokine release syndrome030104 developmental biologyOncology030220 oncology & carcinogenesisCancer researchLymphoma Large B-Cell DiffusebusinessDiffuse large B-cell lymphomamedicine.drugRecent patents on anti-cancer drug discovery
researchProduct

Mimiviruses and the Human Interferon System: Viral Evasion of Classical Antiviral Activities, But Inhibition By a Novel Interferon-β Regulated Immuno…

2017

International audience; In this review we discuss the role of mimiviruses as potential human pathogens focusing on clinical and evolutionary evidence. We also propose a novel antiviral immunomodulatory pathway controlled by interferon-beta (IFN-beta) and mediated by immune-responsive gene 1 (IRG1) and itaconic acid, its product. Acanthamoeba polyphaga Mimivirus (APMV) was isolated from amoebae in a hospital while investigating a pneumonia outbreak. Mimivirus ubiquity and role as protist pathogens are well understood, and its putative status as a human pathogen has been gaining strength as more evidence is being found. The study of APMV and human cells interaction revealed that the virus is …

0301 basic medicineCarboxy-LyasesImmunologyHuman pathogenVirusImmunomodulation03 medical and health sciences[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesInterferon βInterferonVirologymedicineAnimalsHumansGiant VirusGenetic Predisposition to DiseaseGeneMimivirusbiologyProteinsSuccinatesCell BiologyInterferon-betabiology.organism_classificationVirologyDNA Virus Infections3. Good health030104 developmental biologyAcanthamoeba polyphagaHost-Pathogen InteractionsInterferonsMimiviridaemedicine.drugSignal TransductionJournal of interferoncytokine research : the official journal of the International Society for Interferon and Cytokine Research
researchProduct

Gene therapy for chondral and osteochondral regeneration: is the future now?

2017

Gene therapy might represent a promising strategy for chondral and osteochondral defects repair by balancing the management of temporary joint mechanical incompetence with altered metabolic and inflammatory homeostasis. This review analysed preclinical and clinical studies on gene therapy for the repair of articular cartilage defects performed over the last 10 years, focussing on expression vectors (non-viral and viral), type of genes delivered and gene therapy procedures (direct or indirect). Plasmids (non-viral expression vectors) and adenovirus (viral vectors) were the most employed vectors in preclinical studies. Genes delivered encoded mainly for growth factors, followed by transcripti…

0301 basic medicineCartilage ArticularExpression vectorPathologymedicine.medical_specialtyCell signalingCartilage repair; Expression vectors; Gene therapy procedures; Osteoarthritis; Regenerative medicine; Molecular Medicine; Molecular Biology; Pharmacology; Cellular and Molecular Neuroscience; Cell BiologyBone RegenerationInflammatory arthritisGenetic enhancementGene therapy procedureOsteoarthritisViral vector03 medical and health sciencesCellular and Molecular NeuroscienceCartilage repairChondrocytesInterferonSettore BIO/13 - Biologia ApplicataOsteoarthritismedicineAnimalsHumansRegenerationMolecular BiologyPharmacologyExpression vectorbusiness.industryRegeneration (biology)Cell BiologyGenetic Therapymedicine.disease030104 developmental biologyRegenerative medicineCancer researchMolecular MedicineOsteoarthritibusinessmedicine.drugCellular and molecular life sciences : CMLS
researchProduct

Conversion of Nonproliferating Astrocytes into Neurogenic Neural Stem Cells: Control by FGF2 and Interferon-gamma

2016

Abstract Conversion of astrocytes to neurons, via de-differentiation to neural stem cells (NSC), may be a new approach to treat neurodegenerative diseases and brain injuries. The signaling factors affecting such a cell conversion are poorly understood, and they are hard to identify in complex disease models or conventional cell cultures. To address this question, we developed a serum-free, strictly controlled culture system of pure and homogeneous “astrocytes generated from murine embryonic stem cells (ESC).” These stem cell derived astrocytes (mAGES), as well as standard primary astrocytes resumed proliferation upon addition of FGF. The signaling of FGF receptor tyrosine kinase converted G…

0301 basic medicineCell signalingNeurogenesisBiologyInterferon-gammaMice03 medical and health sciences0302 clinical medicineNeural Stem CellsNeurosphereddc:570medicineAnimalsCell ProliferationEpidermal Growth FactorMultipotent Stem CellsCell CycleNeurogenesisMouse Embryonic Stem CellsCell BiologyAnatomyCell DedifferentiationEmbryonic stem cellNeural stem cellCell biologyNeuroepithelial cell030104 developmental biologymedicine.anatomical_structureGene Expression RegulationAstrocytesMolecular MedicineFibroblast Growth Factor 2Stem cell030217 neurology & neurosurgerySignal TransductionDevelopmental BiologyAstrocyte
researchProduct

Signalling strength determines proapoptotic functions of STING

2017

Mammalian cells use cytosolic nucleic acid receptors to detect pathogens and other stress signals. In innate immune cells the presence of cytosolic DNA is sensed by the cGAS–STING signalling pathway, which initiates a gene expression programme linked to cellular activation and cytokine production. Whether the outcome of the STING response varies between distinct cell types remains largely unknown. Here we show that T cells exhibit an intensified STING response, which leads to the expression of a distinct set of genes and results in the induction of apoptosis. Of note, this proapoptotic STING response is still functional in cancerous T cells and delivery of small molecule STING agonists prev…

0301 basic medicineCell typeLeukemia T-CellTranscription Geneticmedicine.medical_treatmentScienceCellsT-LymphocytesGeneral Physics and AstronomyActivationApoptosisInnate Immune SensorBiologyCytosolic DnaCgasGeneral Biochemistry Genetics and Molecular BiologyArticle03 medical and health sciencesCyclic Gmp-Amp[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologymedicineAnimalsReceptorlcsh:ScienceMultidisciplinaryInnate immune systemEffectorQ2nd-MessengerMembrane ProteinsGeneral ChemistryHedgehog signaling pathwayeye diseases3. Good healthCell biologyMice Inbred C57BLSting030104 developmental biologyCytokineDi-GmpImmunologylcsh:QInterferon Regulatory Factor-3Signal transductionTumor Suppressor Protein p53InfectionProtein BindingSignal TransductionNature Communications
researchProduct

Tnfaip3 expression in pulmonary conventional type 1 Langerin‐expressing dendritic cells regulates T helper 2‐mediated airway inflammation in mice

2020

Abstract Background Conventional type 1 dendritic cells (cDC1s) control anti‐viral and anti‐tumor immunity by inducing antigen‐specific cytotoxic CD8+ T‐cell responses. Controversy exists whether cDC1s also control CD4+ T helper 2 (Th2) cell responses, since suppressive and activating roles have been reported. DC activation status, controlled by the transcription factor NF‐κB, might determine the precise outcome of Th‐cell differentiation upon encounter with cDC1s. To investigate the role of activated cDC1s in Th2‐driven immune responses, pulmonary cDC1s were activated by targeted deletion of A20/Tnfaip3, a negative regulator of NF‐κB signaling. Methods To target pulmonary cDC1s, Cd207 (Lan…

0301 basic medicineCellDUSTCD8-Positive T-LymphocytesINHALED ANTIGENTh2&#8208Mice0302 clinical medicineTnfaip3Medicine and Health SciencesCytotoxic T cellImmunology and AllergyInterferon gammaLungSensitizationMice KnockoutCONSTITUTIVE EXPRESSIONIFN-GAMMAbiologyCD8(+) T cellsType 1 conventional dendritic cellsIMMUNE-RESPONSES3. Good healthmedicine.anatomical_structureA20Original Articlemedicine.drugLangerinImmunologyCD8+ T cells03 medical and health sciencesImmune systemTh2 CellsImmunitymedicineAnimalsdriven airway inflammationCD103(+)InflammationBiology and Life SciencesTH2 RESPONSESA20/Tnfaip3Dendritic CellsTh2‐driven airway inflammationMice Inbred C57BL030104 developmental biologyinterferon gamma030228 respiratory systemImmunologybiology.proteinASTHMABasic and Translational Allergy ImmunologyORIGINAL ARTICLESCD8LUNGAllergy
researchProduct

1-ethyl-3-(6-methylphenanthridine-8-il) urea modulates TLR3/9 activation and induces selective pro-inflammatory cytokine expression in vitro.

2017

We have previously demonstrated the nucleic acid binding capacity of phenanthridine derivatives (PHTs). Because nucleic acids are potent inducers of innate immune response through Toll-like receptors (TLRs), and because PTHs bear a structural resemblance to commonly used synthetic ligands for TLR7/8, we hypothesized that PHTs could modulate/activate immune response. We found that compound M199 induces secretion of IL-6, IL-8 and TNFα in human PBMCs and inhibits TLR3/9 activation in different cellular systems (PBMCs, HEK293 and THP-1 cell lines).

0301 basic medicineClinical BiochemistryPharmaceutical ScienceDown-RegulationBiochemistryCell Line03 medical and health sciences0302 clinical medicineImmune systemDrug DiscoveryHumansImmunologic FactorsUreaSecretionReceptorMolecular BiologyInnate immune systemChemistryInterleukin-6Tumor Necrosis Factor-alphaOrganic ChemistryInterleukin-8Interferon-alphaTLR7Molecular biologyphenantridines ; TLR ; PBMCs ; cytokines ; immunomodulationIntercalating AgentsPhenanthridinesToll-Like Receptor 3030104 developmental biologyOligodeoxyribonucleotidesToll-Like Receptor 9TLR3Nucleic acidMolecular MedicineTumor necrosis factor alpha030215 immunologySignal TransductionBioorganicmedicinal chemistry letters
researchProduct

Efficacy and Safety of a Preemptive Antiviral Therapy Strategy Based on Combined Virological and Immunological Monitoring for Active Cytomegalovirus …

2016

Preemptive antiviral therapy for active CMV infection in allogeneic stem cell transplant recipients guided by immunological and virological parameters minimizes the risk of recurrent viremia in a subset of patients.

0301 basic medicineCongenital cytomegalovirus infectionViremiaContext (language use)DiseaseMajor Articles03 medical and health sciences0302 clinical medicineInterferonImmunityallogeneic stem cell transplantationimmunological monitoringMedicineIFN-γ CD8+ T cellscytomegalovirusbusiness.industryvirus diseasesmedicine.disease030104 developmental biologyInfectious DiseasesOncologypreemptive antiviral therapyImmunologyStem cellbusinessCD8030215 immunologymedicine.drugOpen forum infectious diseases
researchProduct

Advances in the treatment of cutaneous lupus erythematosus.

2016

Lupus erythematosus (LE) is a multifactorial autoimmune disease with clinical manifestations of differing severity which may present with skin manifestations as primary sign of the disease (cutaneous lupus erythematosus, CLE) or as part of a disease spectrum (systemic lupus erythematosus, SLE). To date, no drugs are approved specifically for the treatment of CLE and only single agents have been applied in randomized controlled trials. Therefore, topical and systemic agents are used “off-label”, primarily based on open-label studies, case series, retrospective analyses, and expert opinions. In contrast, several agents, such as hydroxychloroquine, chloroquine, cyclophosphamide, azathioprine,…

0301 basic medicineCyclophosphamideDiscoid lupus erythematosusAzathioprineAntibodiesEtanerceptPolyethylene Glycols03 medical and health sciencesLupus Erythematosus DiscoidRheumatologyimmune system diseasesChloroquineMedicineHumansLupus Erythematosus SystemicMolecular Targeted TherapyPrecision Medicineskin and connective tissue diseasesRandomized Controlled Trials as TopicB-LymphocytesLupus erythematosusbusiness.industryInterleukin-6Anti-Inflammatory Agents Non-SteroidalHydroxychloroquinemedicine.diseaseBelimumab030104 developmental biologyImmunologyInterferonsbusinessBiomarkersAnti-SSA/Ro autoantibodiesmedicine.drugSignal TransductionLupus
researchProduct